Advancing our innovative pipeline
to address unmet needs

Overview

We are applying our TransCon technology to build a leading, fully integrated biopharmaceutical company with an independent pipeline of long-acting prodrug therapies that address unmet needs. In addition to our current pipeline of three rare disease endocrinology candidates, we have established oncology as our second therapeutic area of focus.

You are about to access www.ascendispharma.com. Click below if you wish to proceed.
Go



You are about to access www.ascendispharma.com. Click below if you wish to proceed.
Go



You are about to access www.ascendispharma.com. Click below if you wish to proceed.
Go



You are about to access www.ascendispharma.com. Click below if you wish to proceed.
Go